Business Context and Reporting Period
This Form 8-K is a current report filed by Millendo Therapeutics, Inc. (noting the input metadata referenced "Tempest Therapeutics" incorrectly) on June 11, 2019. The filing documents the results of the Company's 2019 Annual Meeting of Stockholders held on that date. The Company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol MLND.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document.
Material Changes and Corporate Actions
The primary material events reported are the stockholder approvals of the following proposals at the Annual Meeting:
- 2019 Equity Incentive Plan: Approved to succeed the 2012 Stock Plan and OvaScience 2012 Stock Incentive Plan, allowing for the grant of stock options, restricted stock units, and other awards.
- 2019 Employee Stock Purchase Plan (ESPP): Approved to enable eligible employees to purchase shares of common stock.
- Election of Directors: Three Class I directors were elected to three-year terms: Julia C. Owens, Ph.D.; Mary Lynne Hedley, Ph.D.; and John Howe, III, M.D.
- Accounting Firm Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2019.
- Executive Compensation: Stockholders approved the compensation of Named Executive Officers on an advisory basis.
Voting Results and Management Commentary
The filing provides detailed vote tabulations for the five proposals. While most proposals received overwhelming support, Proposal 4 (Equity Incentive Plan) saw a notable number of votes against it.
| Proposal | Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (Julia C. Owens) | 10,929,588 | 10,504 (Withheld) | N/A | 609,545 |
| Election of Directors (John Howe, III) | 8,492,214 | 2,447,878 (Withheld) | N/A | 609,545 |
| Ratification of Accounting Firm | 11,428,106 | 14,082 | 107,449 | N/A |
| Executive Compensation | 10,884,612 | 36,011 | 19,469 | 609,545 |
| 2019 Equity Incentive Plan | 8,986,582 | 1,934,299 | 19,211 | 609,545 |
| 2019 Employee Stock Purchase Plan | 10,230,711 | 26,886 | 682,495 | 609,545 |
Management commentary is limited to the description of the Plans, which are incorporated by reference from the Definitive Proxy Statement filed on April 29, 2019. No specific risks or contingencies were disclosed in this specific 8-K text beyond standard governance procedures.
Investor Verification Checklist
- Verify the full terms of the 2019 Equity Incentive Plan and 2019 ESPP by reviewing Exhibits 10.1 and 10.2 attached to this filing.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 29, 2019, for detailed rationale behind the compensation and equity plans.
- Note the significant number of votes withheld for director John Howe, III, M.D. (approx. 22% of votes cast) compared to other nominees.
- Confirm the total number of shares authorized under the new equity plans to assess potential dilution impact.